Table 2.
Vaccine-related response for two anti-Spike antibodies at day 90 after start of vaccination by demographic characteristics
| Day 90 Spike IgG fold change from baseline (log10) (N = 5625) |
Day 90 Spike-ACE2r blocking antibody (AU/mL) (N = 5662) |
|||||
|---|---|---|---|---|---|---|
| <2-fold change | 2- to 3-fold change | >3-fold change | <1 | 1–4 | >4 | |
| Participants, n (% of total) | 281 (5.0) | 1239 (22.0) | 4105 (73.0) | 718 (12.7) | 1380 (24.4) | 3564 (62.9) |
| Age (y), median (IQR) | 66 (55–75) | 69 (56–78) | 64 (54–74) | 73 (60–79) | 73 (59–79) | 62 (53–69) |
| Age group, n (%) | ||||||
| <55 y | 63 (22.4) | 266 (21.5) | 1050 (25.6) | 120 (16.7) | 227 (16.4) | 1038 (29.1) |
| 55–64 y | 69 (24.6) | 223 (18.0) | 1127 (27.5) | 106 (14.8) | 229 (16.6) | 1095 (30.7) |
| 65–74 y | 71 (25.3) | 291 (23.5) | 936 (22.8) | 181 (25.2) | 335 (24.3) | 800 (22.4) |
| ≥75 y | 78 (27.8) | 459 (37.0) | 992 (24.2) | 311 (43.3) | 589 (42.7) | 631 (17.7) |
| Sex, n (%) | ||||||
| Male | 153 (54.4) | 665 (53.7) | 1732 (42.2) | 421 (58.6) | 739 (53.6) | 1400 (39.3) |
| Female | 128 (45.6) | 574 (46.3) | 2373 (57.8) | 297 (41.4) | 641 (46.4) | 2164 (60.7) |
| Vaccine priority group, n (%) | ||||||
| 1. Individuals at increased risk | 190 (67.6) | 401 (32.4) | 760 (18.5) | 369 (51.4) | 432 (31.3) | 560 (15.7) |
| 2. Health-care workers | 5 (1.8) | 28 (2.3) | 131 (3.2) | 8 (1.1) | 26 (1.9) | 132 (3.7) |
| 3. General population | 86 (30.6) | 810 (65.4) | 3214 (78.3) | 341 (47.5) | 922 (66.8) | 2872 (80.6) |
| Vaccine received, n (%) | ||||||
| BTN162b2 | 255 (90.7) | 975 (78.7) | 2020 (49.2) | 667 (92.9) | 1210 (87.7) | 1389 (39.0) |
| mRNA-1273 | 26 (9.3) | 256 (20.7) | 2022 (49.3) | 51 (7.1) | 166 (12.0) | 2106 (59.1) |
| ChAdOx1/mRNA | 0 | 8 (0.6) | 63 (1.5) | 0 | 4 (0.3) | 69 (1.9) |
| Time between first and second dose (d), median (IQR) | 22 (21–27) | 24 (21–35) | 35 (24–35) | 22 (21–26) | 24 (21–28) | 35 (27–35) |
| Time from first vaccine to third study visit (d), median (IQR) | 91 (89–95) | 92 (89–96) | 91 (89–96) | 92 (90–95) | 92 (89–96) | 91 (89–96) |
| Enrolment month in 2021, median (IQR) | March (March–April) | April (March–April) | April (March–May) | March (March–April) | April (March–April) | May (April–May) |
| CCI score categories, n (%) | ||||||
| 0 | 130 (46.3) | 833 (67.2) | 3137 (76.4) | 366 (51.0) | 914 (66.2) | 2843 (79.8) |
| 1–2 | 117 (41.6) | 340 (27.4) | 833 (20.3) | 281 (39.1) | 391 (28.3) | 631 (17.7) |
| >2 | 34 (12.1) | 66 (5.3) | 135 (3.3) | 71 (9.9) | 75 (5.4) | 90 (2.5) |
| Comorbidities, n (%) | ||||||
| Myocardial infarction | 7 (2.5) | 32 (2.6) | 64 (1.6) | 20 (2.8) | 37 (2.7) | 47 (1.3) |
| Congestive heart failure | 13 (4.6) | 49 (4.0) | 75 (1.8) | 37 (5.2) | 46 (3.3) | 54 (1.5) |
| Peripheral vascular disease | 6 (2.1) | 16 (1.3) | 37 (0.9) | 17 (2.4) | 20 (1.4) | 22 (0.6) |
| Cerebrovascular disease Dementia | 14 (5.0) | 53 (4.3) | 123 (3.0) | 44 (6.1) | 62 (4.5) | 86 (2.4) |
| Chronic pulmonary disease | 21 (7.5) | 74 (6.0) | 178 (4.3) | 52 (7.2) | 85 (6.2) | 139 (3.9) |
| Rheumatic disease | 10 (3.6) | 36 (2.9) | 82 (2.0) | 31 (4.3) | 42 (3.0) | 55 (1.5) |
| Peptic ulcer disease | 0 | 7 (0.6) | 15 (0.4) | 6 (0.8) | 7 (0.5) | 9 (0.3) |
| Liver disease | 23 (8.2) | 18 (1.5) | 49 (1.2) | 27 (3.8) | 28 (2.0) | 36 (1.0) |
| Diabetes | 23 (8.2) | 56 (4.5) | 131 (3.2) | 57 (7.9) | 58 (4.2) | 97 (2.7) |
| Hemiplegia or paraplegia | 0 | 2 (0.2) | 3 (0.1) | 1 (0.1) | 1 (0.1) | 3 (0.1) |
| Renal disease | 27 (9.6) | 19 (1.5) | 36 (0.9) | 35 (4.9) | 25 (1.8) | 22 (0.6) |
| Any malignancy | 57 (20.3) | 138 (11.1) | 343 (8.4) | 127 (17.7) | 158 (11.4) | 259 (7.3) |
| Metastatic solid tumour | 3 (1.1) | 7 (0.6) | 16 (0.4) | 5 (0.7) | 7 (0.5) | 14 (0.4) |
| HIV | 2 (0.7) | 12 (1.0) | 22 (0.5) | 8 (1.1) | 12 (0.9) | 16 (0.4) |
| Organ transplantation | 49 (17.4) | 20 (1.6) | 49 (1.2) | 61 (8.5) | 27 (2.0) | 31 (0.9) |
Those who were SARS-CoV-2 PCR or plasma Spike Ig positive at baseline were excluded.